Abstract
To compare the tolerability of quetiapine with risperidone in older outpatients. Post hoc analysis of a subset of older patients (aged 60-80; n = 92) from a randomized, 4-month, multicenter, open-label trial comparing quetiapine and risperidone in an outpatient setting. Participants had various neuropsychiatric disorders associated with psychosis as defined by criteria from the Diagnostic and Statistical Manual of Mental Disorders (4th edn). The main outcome measure was an extrapyramidal symptoms (EPS) checklist, used to assess motor symptoms, including parkinsonism, at baseline and after treatment. The Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression scale were used to assess therapeutic efficacy. Substantial EPS (defined as EPS requiring a dosage adjustment or use of medication to reduce EPS) occurred less often with quetiapine (median dosage, 200 mg/day) than with risperidone (median dosage, 3 mg/day); odds ratio, 0.31 (P < 0.03). Quetiapine was also less likely than risperidone to cause akathisia or hypertonia. Both compounds produced comparable reductions in PANSS scores. Interpretation of findings in this report is limited by the open-label design of the study and the post hoc nature of this...Continue Reading
References
Jun 1, 1995·The British Journal of Psychiatry : the Journal of Mental Science·J Peuskens
Aug 15, 1997·Biological Psychiatry·L A Arvanitis, B G Miller
Jun 18, 1998·Psychopharmacology·D J KingB Kowalcyk
Nov 5, 1999·The Journal of Clinical Psychiatry·P N TariotC A Podgorski
Jan 6, 2000·Current Medical Research and Opinion·B Green
Jun 22, 2000·International Journal of Geriatric Psychiatry·M DavidsonM Haushofer
Oct 26, 2000·Clinical Therapeutics·P N TariotI W Rak
Oct 29, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·V Dev, J Raniwalla
Mar 10, 2001·Drugs & Aging·M J ByerlyE Lescouflair
Mar 16, 2001·Expert Opinion on Pharmacotherapy·R C Love, M W Nelson
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S Kasper, F Müller-Spahn
Jul 4, 2001·Pharmacopsychiatry·W W FleischhackerB van Baelen
Jan 5, 2002·Journal of Clinical Psychopharmacology·J P HwangS J Tsai
Jan 5, 2002·Clinical Therapeutics·J MullenD Sweitzer
Jan 17, 2002·Pharmacotherapy·Vicki L EllingrodStephan Arndt
Mar 23, 2002·Journal of Clinical Psychopharmacology·Yoram BarakRonit Weizman
Apr 17, 2002·Schizophrenia Research·Hülya ErbağciErdem Gümüşburun
Apr 26, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·R Bullock, S Libretto
Jun 26, 2003·The Journal of Clinical Psychiatry·Catherine S FontaineMyron F Weiner
Sep 2, 2003·International Journal of Geriatric Psychiatry·Philip D HarveyGeorges Gharabawi
Citations
Dec 31, 2010·Indian Journal of Pharmacology·Ruchita ShahNidhi Malhotra
Mar 27, 2007·Journal of Affective Disorders·Caleb M AdlerStephen M Strakowski
Feb 14, 2007·The American Journal of Geriatric Pharmacotherapy·Rehan AzizRajesh R Tampi
May 19, 2005·Pharmacotherapy·Richard R Riker, Gilles L Fraser
May 10, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Akiko KobayashiYoshio Hirayasu
Jan 21, 2011·The Cochrane Database of Systematic Reviews·Katja KomossaStefan Leucht
Nov 20, 2013·The Cochrane Database of Systematic Reviews·Laila AsmalStefan Leucht
Nov 11, 2006·International Journal of Geriatric Psychiatry·Lorenz HilwerlingStefan Georg Schröder
Sep 20, 2007·International Journal of Geriatric Psychiatry·D PaleacuD Mazeh
Sep 1, 2007·Journal of Clinical Neurology·Jeong-Min KimManho Kim
Dec 24, 2005·Harvard Review of Psychiatry·Dilip V JesteCarl Salzman
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Adib Essali, Ghassan Ali
Jun 18, 2009·Therapeutic Drug Monitoring·Alfonso M LostiaRoberto Tatarelli
Jul 7, 2005·International Journal of Geriatric Psychiatry
Aug 3, 2021·Expert Opinion on Pharmacotherapy·Fayçal MouaffakPierre-Michel Llorca